Potential role of aromatase inhibitors in the treatment of endometriosis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Endometriosis is an estrogen-dependent chronic inflammatory disease affecting 5%-10% of reproductive-age women, with a prevalence of 5%-50% in infertile women and >33% of women with chronic pelvic pain. Third-generation aromatase inhibitors (AIs) are approved adjuvants for the treatment of estrogen receptor-positive breast cancer. Molecular studies have revealed the presence of aromatase P450, the key enzyme in the biosynthesis of ovarian estradiol, inside the endometriotic tissue, indicating local synthesis of estradiol. Thereby, AIs represent an appealing medical option for the management of different aspects of this enigmatic disease, especially pelvic pain and infertility. Accordingly, this review aims to evaluate the potential role of AIs in the treatment of endometriosis-associated symptoms, mainly pain and infertility. Notably, several studies have demonstrated that the combination of AIs with conventional therapy as oral contraceptive pills, progestins, or gonadotropin-releasing hormone analogs can be used to control endometriosis-associated pain and pain recurrence in premenopausal women, particularly those with pain due to rectovaginal endometriosis refractory to other medical or surgical treatment. Some case reports have shown promising results in the treatment of postmenopausal endometriosis as first-line treatment, when surgery is contraindicated, or as second-line treatment in the case of postoperative recurrence. Third-generation AIs, especially letrozole, have challenged clomiphene citrate as an ovulation-induction agent in patients with polycystic ovary syndrome and in cases of unexplained infertility. However, few studies are available regarding the use of AIs to treat endometriosis-associated infertility. Therefore, larger multicenter randomized trials using AIs for the treatment of endometriosis-associated infertility are needed to clarify its effect. The safety of AIs for ovulation induction or superovulation has generated a lively discussion. Data from recent retrospective and prospective studies have supported its safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211 · cited 5×
“35,36,55,56 In a retrospective controlled study, Werbrouck et al 57 concluded that performing intrauterine insemination with controlled ovarian stimulation within 6 months after surgical treatment in infertile women with minimal–mild endometriosis may be beneficial, since pregnancy rates were…”
InfluentialGiudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924 · cited 2×
“Patients can present with a wide range of symptoms; however, the cardinal clinical features are infertility and chronic pelvic pain.(4) In te rn at io na l J ou rn al o f W om en 's H ea lth d ow nl oa de d fr om h ttp s: //w w w .”
Pathogenesis and pathophysiology of endometriosis
Burney, R. O., & Giudice, L. C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.029 · Cited by 1,590
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 1×
“59 Letrozole’s ovulation-inducing effects have been attributed to the inhibition of androgen–estrogen conversion, thus releasing the hypothalamus–pituitary axis from negative feedback and increasing secretion of pituitary FSH. Additionally, increased follicular sensitivity to FSH owing to increased…”
Practice Bulletin No. 114: Management of Endometriosis
(2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181e8b073 · Cited by 382
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 5×
“21 Analysis of the case series/reports showed that AIs combined with progestins or the oral contraceptive pill or GnRHas reduced mean pain scores and lesion size and improved quality of life.”
InfluentialThe Outcome of 150 Babies Following the Treatment With Letrozole or Letrozole and Gonadotropins
Biljan, M. M., Hemmings, R., & Brassard, N. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.230 · Cited by 206 · cited 1×
“A poorly done abstract published by the ASRM in 2005, 73 which never resulted in a paper, raised concerns of increased cardiac and bone malformations in new-borns of letrozole-treated pregnancies compared with controls.”
A new era in ovulation induction
Holzer, H., Casper, R., & Tulandi, T. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.078 · Cited by 194 · cited 2×
“60,61 Accordingly, letrozole has challenged CC as an ovulation-induction agent in patients with polycystic ovary syndrome, 62,63–66 and in cases of unexplained infertility.”
Influential
Cited by
Endometriosis: where are we and where are we going?
Greene, A. D., Lang, S. A., Kendziorski, J. A., Sroga-Rios, J. M., Herzog, T. J., & Burns, K. A. (2016) · Reproduction · doi:10.1530/rep-16-0052 · Cited by 187
DNA methylation in endometriosis (Review)
KOUKOURA, O., SIFAKIS, S., & SPANDIDOS, D. A. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4925 · Cited by 103
Prolactin concentration in various stages of endometriosis in infertile women
Mirabi, P., Alamolhoda, S. H., Golsorkhtabaramiri, M., Namdari, M., & Esmaeilzadeh, S. (2019) · JBRA Assisted Reproduction · doi:10.5935/1518-0557.20190020 · Cited by 25
Metadata
- Authors
- Abu Hashim, H.
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2014-07
- Volume
- 6
- Pages
- 671
- ISSN
- 1179-1411 (ISSN-L)
- OpenAlex
- W2040426678
- Cited by
- 46
- References
- 20
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.